NASDAQ:PRQR ProQR Therapeutics Q3 2025 Earnings Report $1.65 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.66 +0.01 (+0.30%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ProQR Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS -$0.10Beat/MissMissed by -$0.02One Year Ago EPSN/AProQR Therapeutics Revenue ResultsActual Revenue$3.38 millionExpected Revenue$7.05 millionBeat/MissMissed by -$3.67 millionYoY Revenue GrowthN/AProQR Therapeutics Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time9:30AM ETUpcoming EarningsProQR Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) ProQR Therapeutics Earnings HeadlinesProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorSeptember 23, 2026 | globenewswire.comProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 23, 2026 | americanbankingnews.comOne signature away. Expected within months.On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on American soil. Congress had 25 days notice and raised no objections. The company's own filings cite substantial support and partnership from the Department of War. Alongside gold, the deposit holds a second metal China has banned from export to the U.S., the only domestic reserve of its kind. The company is roughly one fiftieth the size of Newmont.September 28 at 1:00 AM | Behind the Markets (Ad)ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease TreatmentSeptember 10, 2026 | finance.yahoo.comProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026September 9, 2026 | globenewswire.comProQR to Participate in Upcoming Investor Conferences in September 2026September 2, 2026 | globenewswire.comSee More ProQR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProQR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProQR Therapeutics and other key companies, straight to your email. Email Address About ProQR TherapeuticsProQR Therapeutics (NASDAQ:PRQR) (NASDAQ: PRQR) is a biotechnology company focused on developing RNA-based medicines for genetic and other serious diseases. The company’s research platform is designed to modify RNA and potentially correct disease-causing genetic defects without permanently changing a patient’s DNA. ProQR has primarily pursued treatments for inherited retinal disorders and other conditions affecting the eye. Its pipeline has included investigational RNA therapies such as sepofarsen, developed for Leber congenital amaurosis type 10, and ultevursen, developed for Usher syndrome type 2A. The company’s programs and development priorities may change as clinical testing and regulatory evaluation progress. Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR operates internationally through research, development and strategic collaboration activities. Its RNA-editing technology has also supported partnerships with larger pharmaceutical companies, including Eli Lilly. Daniel A. de Boer has served as the company’s chief executive officer and co-founder.View ProQR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
